DK2975028T3 - Pyrazolamid-forbindelse og medicinske anvendelser heraf - Google Patents
Pyrazolamid-forbindelse og medicinske anvendelser heraf Download PDFInfo
- Publication number
- DK2975028T3 DK2975028T3 DK14763385.3T DK14763385T DK2975028T3 DK 2975028 T3 DK2975028 T3 DK 2975028T3 DK 14763385 T DK14763385 T DK 14763385T DK 2975028 T3 DK2975028 T3 DK 2975028T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- diabetes
- pharmaceutically acceptable
- acceptable salt
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (19)
1. Forbindelse, som er repræsenteret ved formel [I]:
hvor n er 1 eller 2, eller et farmaceutisk acceptabelt salt deraf eller et solvat deraf.
2. Forbindelse ifølge krav 1, som er repræsenteret ved formlen:
3. Forbindelse ifølge krav 2, som er repræsenteret ved formel [II]:
4. Forbindelse ifølge krav 2, som er repræsenteret ved formel [IIh]:
5. Forbindelse ifølge krav 1, som er repræsenteret ved formel [III]:
6. Farmaceutisk sammensætning omfattende forbindelsen ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf eller et solvat deraf og en farmaceutisk acceptabel bærer.
7. PDHK-inhibitor omfattende forbindelsen ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf eller et solvat deraf.
8. PDHK1-inhibitor omfattende forbindelsen ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf eller et solvat deraf.
9. PDHK2-inhibitor omfattende forbindelsen ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf eller et solvat deraf.
10. Hypoglykæmisk middel omfattende forbindelsen ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf eller et sol- vat deraf.
11. Mælkesyresænkende middel omfattende forbindelsen ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf eller et solvat deraf.
12. Forbindelse ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf eller et solvat deraf, til anvendelse ved forebyggelse eller behandling af diabetes, insulinresistenssyndrom, metabolisk syndrom, hyperglykæmi, hyperlaktacidæmi, diabetiske komplikationer, hjertesvigt, kardiomyopati, myokardieiskæmi, myokardieinfarkt, angina pectoris, dyslipidæmi, aterosklerose, perifer arteriesygdom, claudicatio intermittens, kronisk obstruktiv lungesygdom, hjerneiskæmi, cerebral apopleksi, mitokon-driesygdom, mitokondriel encefalomyopati, cancer eller pulmonal hypertension.
13. Forbindelse til anvendelse ifølge krav 12, hvor diabetes er type 1-diabetes eller type 2-diabetes.
14. Forbindelse til anvendelse ifølge krav 12, de diabetiske komplikationer er udvalgt fra gruppen bestående af diabetisk neuropati, diabetisk retinopati, diabetisk nefropati og katarakt.
15. Forbindelse til anvendelse ifølge krav 12, hvor hjertesvigt er akut hjertesvigt eller kronisk hjertesvigt.
16. Middel til anvendelse ved forebyggelse eller behandling af diabetes, insulinresistenssyndrom, metabolisk syndrom, hyperglykæmi, hyperlaktacidæmi, diabetiske komplikationer, hjertesvigt, kardiomyopati, myokardieiskæmi, myokardieinfarkt, angina pectoris, dyslipidæmi, aterosklerose, perifer arteriesygdom, claudicatio intermittens, kronisk obstruktiv lungesygdom, hjerneiskæmi, cerebral apopleksi, mitokondriesygdom, mitokondriel encefalomyopati, cancer eller pulmonal hypertension, som omfatter forbindelsen ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf eller et solvat deraf.
17. Middel til anvendelse ifølge krav 16, hvor diabetes er type 1-diabetes eller type 2-diabetes.
18. Middel til anvendelse ifølge krav 16, hvor de diabetiske komplikationer er udvalgt fra gruppen bestående af diabetisk neuropati, diabetisk retinopati, diabetisk nefropati og katarakt.
19. Middel til anvendelse ifølge krav 16, hvor hjertesvigt er akut hjertesvigt eller kronisk hjertesvigt.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791164P | 2013-03-15 | 2013-03-15 | |
JP2013053195 | 2013-03-15 | ||
JP2013127318 | 2013-06-18 | ||
PCT/JP2014/056825 WO2014142290A1 (ja) | 2013-03-15 | 2014-03-14 | ピラゾール-アミド化合物およびその医薬用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2975028T3 true DK2975028T3 (da) | 2018-03-12 |
Family
ID=51536938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14763385.3T DK2975028T3 (da) | 2013-03-15 | 2014-03-14 | Pyrazolamid-forbindelse og medicinske anvendelser heraf |
Country Status (31)
Country | Link |
---|---|
US (4) | US9040717B2 (da) |
EP (3) | EP2975028B1 (da) |
JP (6) | JP6208603B2 (da) |
KR (1) | KR102226096B1 (da) |
CN (1) | CN105051015B (da) |
AU (1) | AU2014230569B2 (da) |
BR (1) | BR112015022077A2 (da) |
CA (1) | CA2904985C (da) |
CL (1) | CL2015002608A1 (da) |
CY (1) | CY1120173T1 (da) |
DK (1) | DK2975028T3 (da) |
ES (1) | ES2663789T3 (da) |
HK (1) | HK1215808A1 (da) |
HR (1) | HRP20180635T1 (da) |
HU (1) | HUE036672T2 (da) |
IL (1) | IL241355B (da) |
LT (1) | LT2975028T (da) |
ME (1) | ME03090B (da) |
MX (1) | MX2015012743A (da) |
MY (1) | MY182884A (da) |
NO (1) | NO2975028T3 (da) |
PE (1) | PE20151595A1 (da) |
PH (1) | PH12015501993A1 (da) |
PL (1) | PL2975028T3 (da) |
PT (1) | PT2975028T (da) |
RS (1) | RS57188B1 (da) |
RU (1) | RU2664532C2 (da) |
SG (1) | SG11201507327TA (da) |
SI (1) | SI2975028T1 (da) |
TW (1) | TWI633885B (da) |
WO (1) | WO2014142290A1 (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
BR112015016793B1 (pt) | 2013-01-15 | 2021-12-28 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
SI2975028T1 (en) * | 2013-03-15 | 2018-07-31 | Japan Tobacco, Inc. | PIRAZOL-AMIDIC COMPOUNDS AND MEDICINAL USE FORM |
US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
RU2736722C2 (ru) * | 2016-07-29 | 2020-11-19 | Джапан Тобакко Инк. | Способ получения соединения пиразоламида |
TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
TWI803570B (zh) * | 2018-02-01 | 2023-06-01 | 日商日本香煙產業股份有限公司 | 含氮雜環醯胺化合物以及其醫藥用途 |
JPWO2020054734A1 (ja) * | 2018-09-11 | 2021-08-30 | 日本たばこ産業株式会社 | ピラゾール−アミド化合物を含有する慢性腎臓病の治療又は予防剤 |
US20220409548A1 (en) | 2019-03-04 | 2022-12-29 | Japan Tobacco Inc. | Amorphous solid dispersion of pyrazole-amide compound |
JP2022007994A (ja) * | 2020-03-04 | 2022-01-13 | 日本たばこ産業株式会社 | 縮合三環性化合物及びその医薬用途 |
CA3228249A1 (en) * | 2021-09-01 | 2023-03-09 | Maki YAMAKAWA | Nitrogen-containing tricyclic compound and pharmaceutical use thereof |
KR20240045387A (ko) * | 2022-09-28 | 2024-04-08 | (주)제이디바이오사이언스 | 신규한 플루오렌 유도체 및 이의 용도 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2827285B1 (fr) * | 2001-07-10 | 2003-12-05 | Rhodia Chimie Sa | Reactif et procede pour la perfluoroalcoylation |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
US7098241B2 (en) | 2002-12-16 | 2006-08-29 | Hoffmann-La Roche Inc. | Thiophene hydroxamic acid derivatives |
WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
AU2005214249A1 (en) | 2004-02-20 | 2005-09-01 | Astellas Pharma Inc. | Fluorene derivative |
FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
RU2007147844A (ru) * | 2005-05-23 | 2009-06-27 | Джапан Тобакко Инк. (Jp) | Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета |
US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
FR2936173B1 (fr) * | 2008-09-22 | 2012-09-21 | Snecma | Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta |
AR074797A1 (es) | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
JPWO2010123016A1 (ja) * | 2009-04-22 | 2012-10-25 | アステラス製薬株式会社 | カルボン酸化合物 |
SI2975028T1 (en) * | 2013-03-15 | 2018-07-31 | Japan Tobacco, Inc. | PIRAZOL-AMIDIC COMPOUNDS AND MEDICINAL USE FORM |
JP2014198712A (ja) | 2013-03-15 | 2014-10-23 | 日本たばこ産業株式会社 | フルオレン化合物の水和物、およびその結晶 |
TW201536749A (zh) | 2013-07-01 | 2015-10-01 | Japan Tobacco Inc | 吡唑-醇化合物及其醫藥用途 |
WO2015002118A1 (ja) | 2013-07-01 | 2015-01-08 | 日本たばこ産業株式会社 | フルオレン-アミド化合物およびその医薬用途 |
-
2014
- 2014-03-14 SI SI201430703T patent/SI2975028T1/en unknown
- 2014-03-14 BR BR112015022077A patent/BR112015022077A2/pt not_active Application Discontinuation
- 2014-03-14 MX MX2015012743A patent/MX2015012743A/es active IP Right Grant
- 2014-03-14 PL PL14763385T patent/PL2975028T3/pl unknown
- 2014-03-14 DK DK14763385.3T patent/DK2975028T3/da active
- 2014-03-14 NO NO14763385A patent/NO2975028T3/no unknown
- 2014-03-14 EP EP14763385.3A patent/EP2975028B1/en active Active
- 2014-03-14 TW TW103109400A patent/TWI633885B/zh active
- 2014-03-14 KR KR1020157028869A patent/KR102226096B1/ko active IP Right Grant
- 2014-03-14 ES ES14763385.3T patent/ES2663789T3/es active Active
- 2014-03-14 SG SG11201507327TA patent/SG11201507327TA/en unknown
- 2014-03-14 US US14/210,746 patent/US9040717B2/en active Active
- 2014-03-14 WO PCT/JP2014/056825 patent/WO2014142290A1/ja active Application Filing
- 2014-03-14 RS RS20180492A patent/RS57188B1/sr unknown
- 2014-03-14 HU HUE14763385A patent/HUE036672T2/hu unknown
- 2014-03-14 CA CA2904985A patent/CA2904985C/en active Active
- 2014-03-14 CN CN201480016173.0A patent/CN105051015B/zh active Active
- 2014-03-14 PT PT147633853T patent/PT2975028T/pt unknown
- 2014-03-14 LT LTEP14763385.3T patent/LT2975028T/lt unknown
- 2014-03-14 RU RU2015144182A patent/RU2664532C2/ru active
- 2014-03-14 JP JP2014050964A patent/JP6208603B2/ja active Active
- 2014-03-14 MY MYPI2015703124A patent/MY182884A/en unknown
- 2014-03-14 EP EP20204677.7A patent/EP3805205A1/en not_active Withdrawn
- 2014-03-14 AU AU2014230569A patent/AU2014230569B2/en not_active Ceased
- 2014-03-14 EP EP18156002.0A patent/EP3348545A1/en not_active Withdrawn
- 2014-03-14 PE PE2015001993A patent/PE20151595A1/es active IP Right Grant
-
2015
- 2015-04-22 US US14/692,846 patent/US20160074364A1/en not_active Abandoned
- 2015-09-08 PH PH12015501993A patent/PH12015501993A1/en unknown
- 2015-09-09 IL IL241355A patent/IL241355B/en active IP Right Grant
- 2015-09-11 CL CL2015002608A patent/CL2015002608A1/es unknown
-
2016
- 2016-04-01 HK HK16103742.7A patent/HK1215808A1/zh not_active IP Right Cessation
-
2017
- 2017-09-07 JP JP2017171644A patent/JP2018021061A/ja not_active Ceased
- 2017-10-06 US US15/726,569 patent/US20180256547A1/en not_active Abandoned
-
2018
- 2018-03-14 ME MEP-2018-110A patent/ME03090B/me unknown
- 2018-04-20 CY CY20181100419T patent/CY1120173T1/el unknown
- 2018-04-23 HR HRP20180635TT patent/HRP20180635T1/hr unknown
- 2018-07-05 JP JP2018128272A patent/JP2018188449A/ja not_active Ceased
-
2019
- 2019-06-06 JP JP2019105806A patent/JP2019194197A/ja not_active Ceased
- 2019-07-02 US US16/459,959 patent/US20200163937A1/en not_active Abandoned
-
2020
- 2020-08-05 JP JP2020133190A patent/JP2020189855A/ja not_active Ceased
-
2021
- 2021-09-22 JP JP2021153931A patent/JP2022000453A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2975028T3 (da) | Pyrazolamid-forbindelse og medicinske anvendelser heraf | |
EP3353156A1 (en) | Tead transcription factor autopalmitoylation inhibitors | |
US20150018403A1 (en) | Fluorene-amide compounds and pharmaceutical use thereof | |
US20150025120A1 (en) | Pyrazole-alcohol compounds and pharmaceutical use thereof | |
US20140296316A1 (en) | Hydrate and crystal of fluorene compounds | |
NZ712292B2 (en) | Pyrazole-amide compound and medicinal uses therefor | |
NZ712292A (en) | Pyrazole-amide compound and medicinal uses therefor | |
EP2379517B1 (en) | Arylcyclopropylacetamide derivatives useful as glucokinase activators | |
US20230310376A1 (en) | Prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis | |
CN117242076A (zh) | 基于噻吩的化合物及其作为bckdk抑制剂的用途 | |
BR112015016433B1 (pt) | Uso de um composto de formula (i) para tratar um disturbio associado com a tensão do dobramento incorreto da proteína |